Abstract
Background Rupture and dissection are feared complications of ascending thoracic aortic aneurysms caused by mechanical failure of the wall. Currently, the largest aortic diameter is used to predict the risk of wall failure and to determine the need for surgical resection. However, this criterion lacks accuracy, and other prospective parameters are required to predict aneurysm rupture or dissection.
Methods To identify better predictors, we performed a retrospective personalized failure risk analysis, including clinical, geometrical, histological and mechanical data of 33 patients. Uniaxial tensile tests until failure were performed to determine the wall strength. Material parameters were fitted against ex vivo planar biaxial data and in vivo pressure-diameter relationships at diastole and systole. Using the resulting material properties and in vivo data, the maximal in vivo stress at systole was calculated, assuming a thin-walled axisymmetric geometry. The retrospective failure risk, defined as the ratio between the maximal stress and maximal strength, was correlated with prospective parameters to find the best failure risk predictor.
Results Our results show that the distensibility coefficient, which reflects aortic compliance and is derived from pressure measurements and multiphasic scans, outperforms other predictors in assessing the risk of aneurysm failure.
Conclusions In a clinical setting, multiphasic CT-scans followed by the calculation of the distensibility coefficient can be of added benefit in patient-specific, clinical decision making. Additionally, the distensibility derived from the aneurysm volume has the best predictive power as it also takes the axial stretch into account.
Clinical trial URL: https://clinicaltrials.gov/ct2/show/NCT03142074?cond=Aneurysm+Ascending+Aorta&cntry=BE&city=Leuven&draw=2&rank=1
What is new?The distensibility coefficient, which reflects the capacity of the vessel to expand during pressure changes, outperforms purely geometrical predictors when assessing the rupture or dissection risk of ascending thoracic aortic aneurysms.
Not only the change in diameter, but also the change in axial length is important to assess the risk of aneurysm failure. Both dimensions are considered when the change in aneurysm volume is measured.
What are the clinical implications?To quantify the distensibility when determining the need for surgery, the aneurysm should be visualized at two phases, i.e. at diastole and systole. Therefore, ECG-triggered scans with at least two phases need to be included in clinical practice.
Clinicians can add this new metric to their risk stratification process, where it can gradually replace purely geometrical predictors as the database and hence confidence in a cut-off value grows.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03142074
Funding Statement
Research Foundation - Flanders (FWO) (Grants no: SB1SA9119N, SB1S56317) KU Leuven (C2-ADAPT)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee Research UZ/KU Leuven (NCT03142074) and patient informed consent was obtained.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵• Joint last author
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos